Regorafenib Combined With Fulvestrant in Recurrent Low-Grade Serous Ovarian Cancer

This trial is testing a combination of two drugs — regorafenib (a targeted cancer drug) and fulvestrant (a hormone-blocking drug) — in people with recurrent low-grade serous ovarian cancer. This type of ovarian cancer grows slowly but is often resistant to chemotherapy, and the trial explores whether blocking both tumor blood vessels and hormone signals might help. **You may be eligible if...** - You have recurrent low-grade serous ovarian cancer - Your cancer can be measured on scans (at least one measurable tumor) - You have had up to 5 prior lines of therapy - Prior hormone therapy (like letrozole) or MEK inhibitors are acceptable - You are 18 or older with a performance status of 0–2 - You are expected to live at least 12 weeks - Your blood counts and organ function are in an acceptable range **You may NOT be eligible if...** - You have received prior anti-angiogenesis therapy other than bevacizumab - You have significant uncontrolled high blood pressure or heart disease - You have had major surgery or serious bleeding within 4 weeks - You are pregnant or breastfeeding - You have certain uncontrolled infections or clotting disorders Talk to your doctor to see if this trial is right for you.